Compare Archer Aviation Inc (ACHR) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer Aviation Inc vs Incyte Corporation — how do they compare? Archer Aviation Inc trades at $4.89 (market cap $3.76B), while Incyte Corporation trades at $116.98 (market cap $23.10B). The key difference: Incyte Corporation is far larger — about 6.1× Archer Aviation Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | INCY | |
|---|---|---|
Market Cap | $3.76B | $23.10B |
Sector | Industrials | Health |
52-Week High | $13.64 | $118.05 |
52-Week Low | $4.68 | $67.38 |
Enterprise Value | $2.11B | $19.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
